Latest Earnings Results: Q2 '26
Estimated EPS
$0.06
Reported EPS
$0.18
Surprise
+210.1%
Estimated Rev
$295.51M
Reported Rev
$307.96M
Surprise
+4.21%
• Reported GAAP EPS of $0.18 up 12.50% YoY • Reported revenue of $307.96M up 16.40% YoY • Acadia Pharmaceuticals updated full year 2026 total revenue guidance to a range of $1.24 to $1.30 billion, reflecting higher DAYBUE guidance of $480 to $510 million and reaffirmed NUPLAZID guidance.
Bullish Takeaway
Acadia Pharmaceuticals achieved strong commercial execution with double-digit revenue growth across both DAYBUE and NUPLAZID franchises, while receiving a positive regulatory opinion for DAYBUE in the European Union.
Bearish Takeaway
Acadia Pharmaceuticals experienced higher operating expenses, specifically in selling, general and administrative costs and research and development, while facing ongoing structural risks regarding product commercialization and clinical trial outcomes.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | $0.19 | -- | -- | N/A |
Q2 '26 | $0.06 | $0.18 | 210.10% | BEAT |
Q1 '26 | $0.05 | $0.02 | -60.40% | MISSED |
Q4 '25 | $0.14 | $1.60 | 1067.76% | BEAT |
Q3 '25 | $0.14 | $0.42 | 197.10% | BEAT |